Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $39,319.38 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 7,162 shares of the business's stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total value of $39,319.38. Following the completion of the transaction, the insider now directly owns 179,313 shares in the company, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aura Biosciences Stock Up 2.1 %

NASDAQ AURA traded up $0.11 on Monday, reaching $5.47. The company had a trading volume of 39,999 shares, compared to its average volume of 200,127. The stock has a market capitalization of $274.73 million, a P/E ratio of -3.12 and a beta of 0.43. The company's fifty day moving average is $6.71 and its 200 day moving average is $8.15. Aura Biosciences, Inc. has a 52-week low of $4.74 and a 52-week high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09). On average, research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Institutional Investors Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in shares of Aura Biosciences in the fourth quarter valued at $50,000. GAMMA Investing LLC boosted its stake in Aura Biosciences by 5,766.9% in the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after purchasing an additional 9,573 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aura Biosciences during the fourth quarter valued at about $87,000. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences in the fourth quarter worth about $127,000. Finally, Harvest Investment Services LLC purchased a new stake in Aura Biosciences in the 4th quarter worth approximately $133,000. Institutional investors own 96.75% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. JMP Securities set a $19.00 price target on Aura Biosciences in a research note on Wednesday, March 26th. HC Wainwright set a $25.00 price objective on Aura Biosciences in a research note on Tuesday, March 25th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $22.75.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.